Regarding immune checkpoint inhibitors direct efficacy in Exon 20 insertion mutant lung cancers, data from retrospective studies suggested similar outcomes as compared to wild-type historical control, and better than classical EGFR mutant patient [8,9]. The gene discussed is EGFR; the disease is lung carcinoma.